Patent application number | Description | Published |
20090275638 | Compositions and Methods for Inhibiting Expression of XBP-1 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1. | 11-05-2009 |
20100120893 | Compositions and Methods for Inhibiting Expression of Transthyretin - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR. | 05-13-2010 |
20100168206 | GNAQ Targeted dsRNA Compositions And Methods For Inhibiting Expression - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ. | 07-01-2010 |
20100293663 | Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement - Polynucleotides useful for improvement of plants are provided. In particular, polynucleotide sequences are provided from plant sources. Polypeptides encoded by the polynucleotide sequences are also provided. The disclosed polynucleotides and polypeptides find use in production of transgenic plants to produce plants having improved properties. | 11-18-2010 |
20110015252 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE - This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene. | 01-20-2011 |
20110152350 | Compositions and Methods for Inhibiting Expression of XBP-1 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1. | 06-23-2011 |
20110184046 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting Glycogen Synthase Kinase-3 (GSK-3), and methods of using the dsRNA to inhibit expression of GSK-3. | 07-28-2011 |
20110263684 | Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid A Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA. | 10-27-2011 |
20120016006 | Compositions And Methods For Increasing Cellular Uptake Of RNAi Via SID-1 - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Systemic RNA Interference Defective-1 (SID-I) gene, and methods of using the dsRNA to inhibit expression of SID-1. | 01-19-2012 |
20120041051 | Compositions And Methods For Inhibiting Expression Of MIG-12 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting MIDI interacting G12-like protein (MIG 12) gene, and methods of using the dsRNA to inhibit expression of MIG 12. | 02-16-2012 |
20120225927 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR. | 09-06-2012 |
20130012572 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting Glycogen Synthase Kinase-3 (GSK-3), and methods of using the dsRNA to inhibit expression of GSK-3. | 01-10-2013 |
20130023580 | Compositions and Methods for Inhibiting Expression of XBP-1 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1. | 01-24-2013 |
20130035371 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE - This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene. | 02-07-2013 |
20140121263 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE - This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene. | 05-01-2014 |
20140179759 | Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid A Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA | 06-26-2014 |
20140194493 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR. | 07-10-2014 |
20140256791 | Compositions and Methods for Inhibiting Expression of XBP-1 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1. | 09-11-2014 |
20150099794 | GNAQ TARGETED dsRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ. | 04-09-2015 |
20160024497 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting Glycogen Synthase Kinase-3 (GSK-3), and methods of using the dsRNA to inhibit expression of GSK-3. | 01-28-2016 |
Patent application number | Description | Published |
20110166058 | ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES - The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF. | 07-07-2011 |
20110263681 | Organic Compositions to Treat Beta-ENaC-Related Diseases - The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC. | 10-27-2011 |
20120115933 | Organic Compositions to Treat Beta-ENaC-Related Diseases - The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC. | 05-10-2012 |
20120115934 | Organic Compositions to Treat Beta-ENaC-Related Diseases - The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC. | 05-10-2012 |
20120122960 | Organic Compositions to Treat Beta-ENaC-Related Diseases - The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC. | 05-17-2012 |
20120129914 | ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES - The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF. | 05-24-2012 |
20120129915 | ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES - The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF. | 05-24-2012 |
20130012571 | Organic Compositions to Treat Beta-ENaC-Related Diseases - The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC. | 01-10-2013 |
20130289094 | Compositions and Methods for Inhibition of PCSK9 Genes - The invention relates to siRNAs targeting a PCSK9 gene, and methods of using siRNAs to inhibit expression of PC-SK9 and to treat PCSK9 related disorders, e.g., hyperlipidemia. | 10-31-2013 |
20140004565 | CELL-BASED BIOPROCESSING | 01-02-2014 |
20140039039 | ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES - The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF. | 02-06-2014 |
20140099666 | COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION OF A BIOLOGICAL PRODUCT - The invention provides compositions and methods for producing a biological product from a host cell. In various embodiments, the biological product is a polypeptide, a metabolite, a nutraceutical, a chemical intermediate, a biofuel, a food additive, or an antibiotic. In one aspect, the invention provides for a method for producing a biological product from a host cell. The method generally comprises contacting the cell with a RNA effector molecule, a portion of which is complementary to a target gene, maintaining the cell in a large-scale bioreactor for a time sufficient to modulate expression of the target gene, wherein the modulation enhances production of the biological product from the cell, and isolating the biological product from the cell. | 04-10-2014 |
20140107179 | ORGANIC COMPOSITIONS TO TREAT Beta-ENaC-RELATED DISEASES - The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC. | 04-17-2014 |
20150275218 | Organic Compositions to Treat Beta-ENaC-Related diseases - The present disclosure relates to RNAi agents useful in methods of treating BetaENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC. | 10-01-2015 |
20150284721 | ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES - The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF. | 10-08-2015 |